docetaxel anhydrous has been researched along with thiotepa in 13 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (thiotepa) | Trials (thiotepa) | Recent Studies (post-2010) (thiotepa) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 2,858 | 408 | 284 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Mileshkin, L; Prince, HM; Rischin, D; Zimet, A | 1 |
| Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G | 1 |
| Cheng, JP; Jia, J; Lu, YL; Ren, J; Wang, XY; Yan, Y; Yuan, YH | 1 |
| Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl | 1 |
| Che, L; Di, L; Jia, J; Jiang, H; Liang, X; Lyerly, HK; Ren, J; Song, G; Wan, F; Wang, X; Yan, Y; Yu, J; Zhang, J; Zhou, X; Zhu, Y | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Bu, XB; Wang, J; Wang, T; Wang, ZG; Yang, L; Yin, GY | 1 |
| Dong, N; Lyerly, HK; Ren, J; Song, Q; Wang, X; Yang, H; Yu, J; Zhou, X | 1 |
| Sakuta, Y; Sato, K; Tsunoda, KI | 1 |
| Gwin, WR; Hobeika, A; Lyerly, HK; Morse, MA; Qiao, G; Ren, J; Song, Q; Wang, X; Zhou, X | 1 |
3 review(s) available for docetaxel anhydrous and thiotepa
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Methylprednisolone; Middle Aged; Paclitaxel; Taxoids; Thiotepa | 2001 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
4 trial(s) available for docetaxel anhydrous and thiotepa
| Article | Year |
|---|---|
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa | 2011 |
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of su
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Thiotepa | 2013 |
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP2B6; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Genotype; Humans; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Taxoids; Thiotepa | 2015 |
6 other study(ies) available for docetaxel anhydrous and thiotepa
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infection Control; Infections; Inflammation; Melphalan; Middle Aged; Mitoxantrone; Mucous Membrane; Multivariate Analysis; Neutropenia; Paclitaxel; Patient Selection; Retrospective Studies; Risk; Taxoids; Thiotepa; Transplantation Conditioning | 2001 |
MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Mucin-1; Neoplastic Cells, Circulating; Receptors, Progesterone; RNA, Messenger; Taxoids; Thiotepa | 2011 |
Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Genetic Association Studies; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Kaplan-Meier Estimate; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Thiotepa; Treatment Outcome | 2015 |
Development of a Multichannel Dialysis Microchip for Bioassay of Drug Efficacy and Retention.
Topics: Antineoplastic Agents; Biological Assay; Cell Death; Docetaxel; Electrophoresis, Microchip; Humans; MCF-7 Cells; Taxoids; Thiotepa; Tumor Cells, Cultured | 2017 |
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP1A1; Docetaxel; Female; Genetic Markers; Humans; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Progression-Free Survival; Survival Analysis; Thiotepa | 2018 |